Metabolic modeling predicts metabolite changes in Mycobacterium tuberculosis

BMC Systems Biology

Volumn 9, Issue 1, 2015, Pages

  Garay, Christopher D ^a   Dreyfuss, Jonathan M ^a,b   Galagan, James E ^a,c,d  

^a Boston University   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c BOSTON UNIVERSITY   (United States)

^d National Emerging Infectious Diseases Laboratories Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; DOSR PROTEIN, MYCOBACTERIUM TUBERCULOSIS; OXYGEN; PHOP PROTEIN, BACTERIA; PROTEIN KINASE; TRANSCRIPTION FACTOR;

BIOLOGICAL MODEL; DEFICIENCY; GENE DELETION; GENE EXPRESSION PROFILING; GENETICS; LIPID METABOLISM; METABOLIC FLUX ANALYSIS; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES;

BACTERIAL PROTEINS; GENE DELETION; GENE EXPRESSION PROFILING; LIPID METABOLISM; METABOLIC FLUX ANALYSIS; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; OXYGEN; PROTEIN KINASES; TRANSCRIPTION FACTORS;

EID: 84941645291     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/s12918-015-0206-7     Document Type: Article

References (112)

1. Baddeley A, Dean A, Dias HM, Falzon D, Floyd K, Baena IG, et al. Global tuberculosis report 2014. World Health Organization. 2014.
2. Udwadia Z, Vendoti D. Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. J Epidemiol Community Health. 2013;67(6):471-2.
3. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill. 2007;12(5):E070517 1.
4. Klopper M, Warren RM, Hayes C, van Pittius NC G, Streicher EM, Muller B, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis. 2013;19(3):449-55.
5. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest. 2009;136(2):420-5.
6. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis. 2008;21(6):587-95.
7. Russell DG, Barry 3rd CE, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science. 2010;328(5980):852-6.
8. Russell DG. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol. 2001;2(8):569-77.
9. Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol. 2006;5(1):39-47.
10. Kaufmann SHE. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol. 2001;1(1):20-30.
11. Carl N. Taming tuberculosis: a challenge for science and society. Cell Host Microbe. 2009;5(3):220-4.
12. Dannenberg Jr AM. Immunopathogenesis of pulmonary tuberculosis. Hosp Pract. 1993;28(1):51-8.
13. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 1998;6(3):107-12.
14. Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nat Med. 2000;6(12):1327-9.
15. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406(6797):735-8.
16. Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun. 2001;69(7):4195-201.
17. Wayne LG, Sohaskey CD. Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol. 2001;55:139-63.
18. Cosma CL, Sherman DR, Ramakrishnan L. The secret lives of pathogenic mycobacteria. Annu Rev Microbiol. 2003;57:641-76.
19. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis. 2004;84(1-2):29-44.
20. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci U S A. 2001;98(13):7534-9.
21. Dasgupta N, Kapur V, Singh KK, Das TK, Sachdeva S, Jyothisri K, et al. Characterization of a two-component system, devR-devS, of Mycobacterium tuberculosis. Tuber Lung Dis. 2000;80(3):141-59.
22. Boon C, Dick T. Mycobacterium bovis response regulator essential for hypoxic dormancy. J Bacteriol. 2002;184(24):6760-7.
23. Park H-D, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol. 2003;48(3):833-43.
24. Rustad TR, Harrell MI, Liao R, Sherman DR. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One. 2008;3(1):e1502.
25. Abramovitch RB, Rohde KH, Hsu FF, Russell DG. aprABC: a Mycobacterium tuberculosis complex-specific locus that modulates pH-driven adaptation to the macrophage phagosome. Mol Microbiol. 2011;80(3):678-94.
26. Voskuil MI, Bartek IL, Visconti K, Schoolnik GK. The response of mycobacterium tuberculosis to reactive oxygen and nitrogen species. Front Microbiol. 2011;2:105.
27. Boshoff HI, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, et al. Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem. 2008;283(28):19329-41.
28. Kumar A, Toledo JC, Patel RP, Lancaster JR, Steyn AJ. Mycobacterium tuberculosis DosS is a redox sensor and DosT is a hypoxia sensor. Proc Natl Acad Sci U S A. 2007;104(28):11568-73.
29. Singh A, Crossman DK, Mai D, Guidry L, Voskuil MI, Renfrow MB, et al. Mycobacterium tuberculosis WhiB3 maintains redox homeostasis by regulating virulence lipid anabolism to modulate macrophage response. PLoS Pathog. 2009;5(8):e1000545.
30. Singh A, Guidry L, Narasimhulu KV, Mai D, Trombley J, Redding KE, et al. Mycobacterium tuberculosis WhiB3 responds to O2 and nitric oxide via its [4Fe-4S] cluster and is essential for nutrient starvation survival. Proc Natl Acad Sci U S A. 2007;104(28):11562-7.
31. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature. 2013;499(7457):178-83.
32. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al. Transcriptional adaptation of Mycobacterium tuberculosis within Macrophages: insights into the phagosomal environment. J Exp Med. 2003;198(5):693-704.
33. Yang X, Nesbitt NM, Dubnau E, Smith I, Sampson NS. Cholesterol metabolism increases the metabolic pool of propionate in Mycobacterium tuberculosis. Biochemistry. 2009;48(18):3819-21.
34. Miner MD, Chang JC, Pandey AK, Sassetti CM, Sherman DR. Role of cholesterol in Mycobacterium tuberculosis infection. Indian J Exp Biol. 2009;47(6):407-11.
35. Chang JC, Miner MD, Pandey AK, Gill WP, Harik NS, Sassetti CM, et al. igr Genes and Mycobacterium tuberculosis cholesterol metabolism. J Bacteriol. 2009;191(16):5232-9.
36. Kendall SL, Burgess P, Balhana R, Withers M, Ten Bokum A, Lott JS, et al. Cholesterol utilization in mycobacteria is controlled by two TetR-type transcriptional regulators: kstR and kstR2. Microbiology. 2010;156(Pt 5):1362-71.
37. Kendall SL, Withers M, Soffair CN, Moreland NJ, Gurcha S, Sidders B, et al. A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosis. Mol Microbiol. 2007;65(3):684-99.
38. Nesbitt NM, Yang X, Fontan P, Kolesnikova I, Smith I, Sampson NS, et al. A thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect Immun. 2010;78(1):275-82.
39. Uhia I, Galan B, Medrano FJ, Garcia JL. Characterization of the KstR-dependent promoter of the gene for the first step of the cholesterol degradative pathway in Mycobacterium smegmatis. Microbiology. 2011;157(Pt 9):2670-80.
40. Russell DG, VanderVen BC, Lee W, Abramovitch RB, Kim MJ, Homolka S, et al. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe. 2010;8(1):68-76.
41. Russell DG, Mwandumba HC, Rhoades EE. Mycobacterium and the coat of many lipids. J Cell Biol. 2002;158(3):421-6.
42. Jamshidi N, Palsson BO. Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets. BMC Syst Biol. 2007;1:26.
43. Beste DJ, Hooper T, Stewart G, Bonde B, Avignone-Rossa C, Bushell ME, et al. GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism. Genome Biol. 2007;8(5):R89.
44. Bonde BK, Beste DJV, Laing E, Kierzek AM, McFadden J. Differential producibility analysis (DPA) of transcriptomic data with metabolic networks: deconstructing the metabolic response of M. tuberculosis. PLoS Comput Biol. 2011;7(6):e1002060.
45. Shi L, Sohaskey CD, Pfeiffer C, Datta P, Parks M, McFadden J, et al. Carbon flux rerouting during Mycobacterium tuberculosis growth arrest. Mol Microbiol. 2010;78(5):1199-215.
46. Colijn C, Brandes A, Zucker J, Lun DS, Weiner B, Farhat MR, et al. Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production. PLoS Comput Biol. 2009;5(8):e1000489.
47. Bordbar A, Lewis NE, Schellenberger J, Palsson BO, Jamshidi N. Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions. Mol Syst Biol. 2010;6:422.
48. Chindelevitch L, Stanley S, Hung D, Regev A, Berger B. MetaMerge: scaling up genome-scale metabolic reconstructions with application to Mycobacterium tuberculosis. Genome Biol. 2012;13(1):r6.
49. Chandrasekaran S, Price ND. Probabilistic integrative modeling of genome-scale metabolic and regulatory networks in Escherichia coli and Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2010;107(41):17845-50.
50. Becker SA, Palsson BO. Context-specific metabolic networks are consistent with experiments. PLoS Comput Biol. 2008;4(5):e1000082.
51. Lewis NE, Hixson KK, Conrad TM, Lerman JA, Charusanti P, Polpitiya AD, et al. Omic data from evolved E. coli are consistent with computed optimal growth from genome-scale models. Mol Syst Biol. 2010;6:390.
52. Raghunathan A, Reed J, Shin S, Palsson B, Daefler S. Constraint-based analysis of metabolic capacity of Salmonella typhimurium during host-pathogen interaction. BMC Syst Biol. 2009;3(1):38.
53. Huthmacher C, Hoppe A, Bulik S, Holzhutter HG. Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis. BMC Syst Biol. 2010;4(1):120.
54. Plata G, Hsiao TL, Olszewski KL, Llinas M, Vitkup D. Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network. Mol Syst Biol. 2010;6:408.
55. Ma H, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, et al. The Edinburgh human metabolic network reconstruction and its functional analysis. Mol Syst Biol. 2007;3(1):135.
56. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci. 2007;104(6):1777-82.
57. Lofthouse EK, Wheeler PR, Beste DJ, Khatri BL, Wu H, Mendum TA, et al. Systems-based approaches to probing metabolic variation within the Mycobacterium tuberculosis complex. PLoS One. 2013;8(9):e75913.
58. Fang X, Wallqvist A, Reifman J. Development and analysis of an in vivo-compatible metabolic network of Mycobacterium tuberculosis. BMC Syst Biol. 2010;4:160.
59. Orth JD, Thiele I, Palsson BO. What is flux balance analysis? Nat Biotechnol. 2010;28(3):245-8.
60. Papin JA, Price ND, Wiback SJ, Fell DA, Palsson BO. Metabolic pathways in the post-genome era. Trends Biochem Sci. 2003;28(5):250-8.
61. Schilling CH, Edwards JS, Palsson BO. Toward metabolic phenomics: analysis of genomic data using flux balances. Biotechnol Prog. 1999;15(3):288-95.
62. Schilling CH, Schuster S, Palsson BO, Heinrich R. Metabolic pathway analysis: basic concepts and scientific applications in the post-genomic era. Biotechnol Prog. 1999;15(3):296-303.
63. Varma A, Palsson BO. Stoichiometric flux balance models quantitatively predict growth and metabolic by-product secretion in wild-type Escherichia coli W3110. Appl Environ Microbiol. 1994;60(10):3724-31.
64. Wagner C, Urbanczik R. The geometry of the flux cone of a metabolic network. Biophys J. 2005;89(6):3837-45.
65. Edwards JS, Palsson BO. Metabolic flux balance analysis and the in silico analysis of Escherichia coli K-12 gene deletions. BMC Bioinformatics. 2000;1:1.
66. Famili I, Forster J, Nielsen J, Palsson BO. Saccharomyces cerevisiae phenotypes can be predicted by using constraint-based analysis of a genome-scale reconstructed metabolic network. Proc Natl Acad Sci U S A. 2003;100(23):13134-9.
67. Fong SS, Palsson BO. Metabolic gene-deletion strains of Escherichia coli evolve to computationally predicted growth phenotypes. Nat Genet. 2004;36(10):1056-8.
68. Brandes A, Lun DS, Ip K, Zucker J, Colijn C, Weiner B, et al. Inferring carbon sources from gene expression profiles using metabolic flux models. PLoS One. 2012;7(5):e36947.
69. Edwards JS, Ibarra RU, Palsson BO. In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data. Nat Biotechnol. 2001;19(2):125-30.
70. Dreyfuss JM, Zucker JD, Hood HM, Ocasio LR, Sachs MS, Galagan JE. Reconstruction and validation of a genome-scale metabolic model for the filamentous fungus Neurospora crassa using FARM. PLoS Comput Biol. 2013;9(7):e1003126.
71. Reznik E, Mehta P, Segre D. Flux imbalance analysis and the sensitivity of cellular growth to changes in metabolite pools. PLoS Comput Biol. 2013;9(8):e1003195.
72. Collins SB, Reznik E, Segre D. Temporal expression-based analysis of metabolism. PLoS Comput Biol. 2012;8(11):e1002781.
73. Lewis NE, Nagarajan H, Palsson BO. Constraining the metabolic genotype-phenotype relationship using a phylogeny of in silico methods. Nat Rev Microbiol. 2012;10(4):291-305.
74. Covert MW, Schilling CH, Palsson B. Regulation of gene expression in flux balance models of metabolism. J Theor Biol. 2001;213(1):73-88.
75. Shlomi T, Cabili MN, Herrgard MJ, Palsson BO, Ruppin E. Network-based prediction of human tissue-specific metabolism. Nat Biotechnol. 2008;26(9):1003-10.
76. Zur H, Ruppin E, Shlomi T. iMAT: an integrative metabolic analysis tool. Bioinformatics. 2010;26(24):3140-2.
77. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry 3rd CE. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem. 2004;279(38):40174-84.
78. Rustad TR, Minch KJ, Ma S, Winkler JK, Hobbs S, Hickey M, et al. Mapping and manipulating the Mycobacterium tuberculosis transcriptome using a transcription factor overexpression-derived regulatory network. Genome Biol. 2014;15(11):502.
79. Mahadevan R, Edwards JS, Doyle 3rd FJ. Dynamic flux balance analysis of diauxic growth in Escherichia coli. Biophys J. 2002;83(3):1331-40.
80. Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog. 2011;7(6):e1002093.
81. Deb C, Daniel J, Sirakova TD, Abomoelak B, Dubey VS, Kolattukudy PE. A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis. J Biol Chem. 2006;281(7):3866-75.
82. Low KL, Rao PS, Shui G, Bendt AK, Pethe K, Dick T, et al. Triacylglycerol utilization is required for regrowth of in vitro hypoxic nonreplicating Mycobacterium bovis bacillus Calmette-Guerin. J Bacteriol. 2009;191(16):5037-43.
83. Daniel J, Deb C, Dubey VS, Sirakova TD, Abomoelak B, Morbidoni HR, et al. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol. 2004;186(15):5017-30.
84. Baek SH, Li AH, Sassetti CM. Metabolic regulation of mycobacterial growth and antibiotic sensitivity. PLoS Biol. 2011;9(5):e1001065.
85. Pérez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martín C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol. 2001;41(1):179-87.
86. Walters SB, Dubnau E, Kolesnikova I, Laval F, Daffe M, Smith I. The Mycobacterium tuberculosis PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis. Mol Microbiol. 2006;60(2):312-30.
87. Gonzalo Asensio J, Maia C, Ferrer NL, Barilone N, Laval F, Soto CY, et al. The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol Chem. 2006;281(3):1313-6.
88. Gonzalo-Asensio J, Malaga W, Pawlik A, Astarie-Dequeker C, Passemar C, Moreau F, et al. Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator. Proc Natl Acad Sci. 2014;111(31):11491-6.
89. Sirakova TD, Thirumala AK, Dubey VS, Sprecher H, Kolattukudy PE. The Mycobacterium tuberculosis pks2 gene encodes the synthase for the hepta- and octamethyl-branched fatty acids required for sulfolipid synthesis. J Biol Chem. 2001;276(20):16833-9.
90. Jackson JGA, Catarina M, Nadia LF, Nathalie B, Françoise L, Carlos Yesid S, et al. The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. 2006.
91. Cox JS, Chen B, McNeil M, Jacobs Jr WR. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature. 1999;402(6757):79-83.
92. Jain M, Petzold CJ, Schelle MW, Leavell MD, Mougous JD, Bertozzi CR, et al. Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids via metabolic coupling. Proc Natl Acad Sci U S A. 2007;104(12):5133-8.
93. Russell WL, Brian CV, Ruth JF, David G. Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem. 2013;288(10):6788-800.
94. Reed MB, Gagneux S, Deriemer K, Small PM, Barry 3rd CE. The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol. 2007;189(7):2583-9.
95. Buglino J, Onwueme KC, Ferreras JA, Quadri LE, Lima CD. Crystal structure of PapA5, a phthiocerol dimycocerosyl transferase from Mycobacterium tuberculosis. J Biol Chem. 2004;279(29):30634-42.
96. Sopko R, Huang D, Preston N, Chua G, Papp B, Kafadar K, et al. Mapping pathways and phenotypes by systematic gene overexpression. Mol Cell. 2006;21(3):319-30.
97. Dubey VS, Sirakova TD, Kolattukudy PE. Disruption of msl3 abolishes the synthesis of mycolipanoic and mycolipenic acids required for polyacyltrehalose synthesis in Mycobacterium tuberculosis H37Rv and causes cell aggregation. Mol Microbiol. 2002;45(5):1451-9.
98. Patil KR, Nielsen J. Uncovering transcriptional regulation of metabolism by using metabolic network topology. Proc Natl Acad Sci U S A. 2005;102(8):2685-9.
99. Oliveira AP, Patil KR, Nielsen J. Architecture of transcriptional regulatory circuits is knitted over the topology of bio-molecular interaction networks. BMC Syst Biol. 2008;2:17.
100. Slayden RA, Jackson M, Zucker J, Ramirez MV, Dawson CC, Crew R, et al. Updating and curating metabolic pathways of TB. Tuberculosis. 2013;93(1):47-59.
101. Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, McKinney JD, Bertozzi CR, et al. Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem Biol. 2012;19(2):218-27.
102. Shlomi T, Cabili MN, Ruppin E. Predicting metabolic biomarkers of human inborn errors of metabolism. Mol Syst Biol. 2009;5:263.
103. Jerby L, Shlomi T, Ruppin E. Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. 2010. 2010-01-01 00:00:00.
104. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T. Predicting selective drug targets in cancer through metabolic networks. 2011.
105. Gille C, Bölling C, Hoppe A, Bulik S, Hoffmann S, Hübner K, et al. HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol Syst Biol. 2010;6(1):411.
106. Bordbar A, Mo ML, Nakayasu ES, Schrimpe-Rutledge AC, Kim YM, Metz TO, et al. Model-driven multi-omic data analysis elucidates metabolic immunomodulators of macrophage activation. 2012.
107. Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, et al. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol. 2010;28(12):1279-85.
108. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol. 2003;48(1):77-84.
109. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article 3.
110. Wu H, Kerr MK, Cui X, Churchill GA. MAANOVA: a software package for the analysis of spotted cDNA microarray experiments. The analysis of gene expression data: methods and software. New York: Springer; 2003. p. 313-41.
111. R Development Core Team. R. A language and environment for statistical computing: R Foundation for Statistical Computing. 2011. Available from: http://www.R-project.org
112. Gudmundsson S, Thiele I. Computationally efficient flux variability analysis. BMC Bioinformatics. 2010;11:489.